Fisher Asset Management LLC Purchases 12,399 Shares of Medpace Holdings, Inc. $MEDP

Fisher Asset Management LLC lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.9% during the third quarter, Holdings Channel.com reports. The institutional investor owned 137,746 shares of the company’s stock after acquiring an additional 12,399 shares during the quarter. Fisher Asset Management LLC’s holdings in Medpace were worth $70,824,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Clarkston Capital Partners LLC purchased a new position in Medpace during the 2nd quarter valued at about $40,569,000. Cibc World Market Inc. bought a new position in shares of Medpace during the third quarter valued at approximately $5,033,000. Brighton Jones LLC increased its holdings in Medpace by 160.4% during the third quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after buying an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Medpace by 150.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock valued at $8,080,000 after buying an additional 9,117 shares during the period. Finally, Baillie Gifford & Co. raised its stake in Medpace by 12.0% in the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after buying an additional 62,503 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Medpace stock opened at $457.47 on Tuesday. The stock has a market cap of $12.98 billion, a PE ratio of 29.90, a price-to-earnings-growth ratio of 2.17 and a beta of 1.44. The stock has a 50-day moving average of $542.14 and a two-hundred day moving average of $539.31. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same quarter in the previous year, the firm earned $3.67 earnings per share. The company’s revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on MEDP shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a research report on Friday, February 13th. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and reduced their target price for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Finally, Barclays lowered their price target on shares of Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a report on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $483.45.

Insiders Place Their Bets

In other Medpace news, CEO August J. Troendle sold 668 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the transaction, the chief executive officer owned 646,184 shares in the company, valued at approximately $381,694,426.96. This represents a 0.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.